• Policy
• Expenses for the major four severe diseases tops KRW 7T
• by Lee, Tak-Sun Jul 1, 2024 05:47am

• Company
• Ilaris’s reimbursement imminent in Korea
• by Eo, Yun-Ho Jul 1, 2024 05:47am

• Opinion
• [Reporter’s View] No innovation without failure
• by Son, Hyung-Min Jul 1, 2024 05:47am

• Company
• GC Cell-Artiva-MSD’s 'CAR-NK' co-R&D deal terminated
• by Kim, Jin-Gu Jun 28, 2024 04:33am

• Company
• KOD will service platform for epilepsy patients next year
• by Lee, Tak-Sun Jun 28, 2024 04:33am

• Company
• MSD seeks to expand NIP subjects for Gardasil
• by Hwang, Byung-woo Jun 28, 2024 04:33am

• Company
• Spinraza tops Q1 revenue in SMA mkt with KRW 17.7 billion
• by Nho, Byung Chul Jun 28, 2024 04:32am

• Policy
• Gov't releases generic drug price comparison study results
• by Lee, Tak-Sun Jun 27, 2024 05:47am

• Company
• 'Increased' competitiveness in autoimmune diseases
• by Son, Hyung-Min Jun 27, 2024 05:47am

• Policy
• Some Akynzeo products recalled due to insufficient API
• by Lee, Hye-Kyung Jun 27, 2024 05:47am